AKBA Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Akebia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.13 |
| 52 Week High | US$2.89 |
| 52 Week Low | US$0.80 |
| Beta | 0.94 |
| 1 Month Change | 18.33% |
| 3 Month Change | 14.52% |
| 1 Year Change | -3.62% |
| 3 Year Change | -12.70% |
| 5 Year Change | -73.24% |
| Change since IPO | -92.02% |
Recent News & Updates
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Mar 20
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Mar 16Recent updates
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Mar 20Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Mar 16Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Jan 22Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Nov 08Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Aug 02Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Shareholder Returns
| AKBA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | -2.4% | -0.2% |
| 1Y | -3.6% | -6.8% | 8.1% |
Return vs Industry: AKBA exceeded the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: AKBA underperformed the US Market which returned 7.9% over the past year.
Price Volatility
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AKBA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKBA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 181 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.
Akebia Therapeutics, Inc. Fundamentals Summary
| AKBA fundamental statistics | |
|---|---|
| Market cap | US$503.17m |
| Earnings (TTM) | -US$69.41m |
| Revenue (TTM) | US$160.18m |
3.1x
P/S Ratio-7.2x
P/E RatioIs AKBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBA income statement (TTM) | |
|---|---|
| Revenue | US$160.18m |
| Cost of Revenue | US$26.15m |
| Gross Profit | US$134.03m |
| Other Expenses | US$203.44m |
| Earnings | -US$69.41m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 83.68% |
| Net Profit Margin | -43.33% |
| Debt/Equity Ratio | -365.5% |
How did AKBA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 08:34 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akebia Therapeutics, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |
| Julian Harrison | BTIG |